Literature DB >> 24606705

Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.

Diane M Da Silva1, Carly A Movius2, Adam B Raff3, Heike E Brand3, Joseph G Skeate2, Michael K Wong4, W Martin Kast5.   

Abstract

Human papillomavirus (HPV) has evolved mechanisms that allow it to evade the human immune system. Studies have shown HPV-mediated suppression of activation of Langerhans cells (LC) is a key mechanism through which HPV16 evades initial immune surveillance. However, it has not been established whether high- and low-risk mucosal and cutaneous HPV genotypes share a common mechanism of immune suppression. Here, we demonstrate that LC exposed to capsids of HPV types 18, 31, 45, 11, (alpha-papillomaviruses) and HPV5 (beta-papillomavirus) similarly suppress LC activation, including lack of costimulatory molecule expression, lack of cytokine and chemokine secretion, lack of migration, and deregulated cellular signaling. In contrast, HPV1 (mu-papillomavirus) induced costimulatory molecule and cytokine upregulation, but LC migration and cellular signaling was suppressed. These results suggest that alpha and beta HPV genotypes, and partially a mu genotype, share a conserved mechanism of immune escape that enables these viruses to remain undetected in the absence of other inflammatory events.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antigen presentation; Antigen presenting cell; Human papillomavirus; Immune escape; Immune suppression; Langerhans cell; Migration

Mesh:

Substances:

Year:  2014        PMID: 24606705      PMCID: PMC3987942          DOI: 10.1016/j.virol.2014.01.031

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  59 in total

1.  Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union Cohort Study.

Authors:  Satu-Maria A Kulmala; Irena P Shabalova; Nikolay Petrovitchev; Kari J Syrjänen; Ulf B Gyllensten; Bo C Johansson; Stina M Syrjänen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-01       Impact factor: 4.254

Review 2.  Langerhans cells and viral immunity.

Authors:  Anthony L Cunningham; Francis Carbone; Teunis B H Geijtenbeek
Journal:  Eur J Immunol       Date:  2008-09       Impact factor: 5.532

3.  Cutaneous human papillomaviruses persist on healthy skin.

Authors:  Kristina Hazard; Anna Karlsson; Kristin Andersson; Henrik Ekberg; Joakim Dillner; Ola Forslund
Journal:  J Invest Dermatol       Date:  2006-10-05       Impact factor: 8.551

4.  Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

Authors:  Jennifer S Smith; Lisa Lindsay; Brooke Hoots; Jessica Keys; Silvia Franceschi; Rachel Winer; Gary M Clifford
Journal:  Int J Cancer       Date:  2007-08-01       Impact factor: 7.396

5.  Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells.

Authors:  Eynav Klechevsky; Rimpei Morita; Maochang Liu; Yanying Cao; Sebastien Coquery; Luann Thompson-Snipes; Francine Briere; Damien Chaussabel; Gerard Zurawski; A Karolina Palucka; Yoram Reiter; Jacques Banchereau; Hideki Ueno
Journal:  Immunity       Date:  2008-09-19       Impact factor: 31.745

6.  Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3.

Authors:  Mark E Scott; Yifei Ma; Lili Kuzmich; Anna-Barbara Moscicki
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

Review 7.  HPV: from infection to cancer.

Authors:  M A Stanley; M R Pett; N Coleman
Journal:  Biochem Soc Trans       Date:  2007-12       Impact factor: 5.407

8.  Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens.

Authors:  Sjoerd H van der Burg; Sytse J Piersma; Annemieke de Jong; Jeanette M van der Hulst; Kitty M C Kwappenberg; Muriel van den Hende; Marij J P Welters; Jon J Van Rood; Gert Jan Fleuren; Cornelis J M Melief; Gemma G Kenter; Rienk Offringa
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-05       Impact factor: 11.205

9.  Production of papillomavirus-based gene transfer vectors.

Authors:  Christopher B Buck; Cynthia D Thompson
Journal:  Curr Protoc Cell Biol       Date:  2007-12

10.  Betapapillomaviruses frequently persist in the skin of healthy individuals.

Authors:  Maurits N C de Koning; Linda Struijk; Jan Nico Bouwes Bavinck; Bernhard Kleter; Jan ter Schegget; Wim G V Quint; Mariet C W Feltkamp
Journal:  J Gen Virol       Date:  2007-05       Impact factor: 3.891

View more
  16 in total

1.  Immunology of Uterine and Vaginal Mucosae: (Trends in Immunology 39, 302-314, 2018).

Authors:  Jordan Z Zhou; Sing Sing Way; Kang Chen
Journal:  Trends Immunol       Date:  2018-03-09       Impact factor: 16.687

2.  Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression.

Authors:  Andrew W Woodham; Adam B Raff; Laura M Raff; Diane M Da Silva; Lisa Yan; Joseph G Skeate; Michael K Wong; Yvonne G Lin; W Martin Kast
Journal:  J Immunol       Date:  2014-04-09       Impact factor: 5.422

Review 3.  Human genetic dissection of papillomavirus-driven diseases: new insight into their pathogenesis.

Authors:  Vivien Béziat
Journal:  Hum Genet       Date:  2020-05-20       Impact factor: 4.132

4.  Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.

Authors:  Diane M Da Silva; Andrew W Woodham; Joseph G Skeate; Laurie K Rijkee; Julia R Taylor; Heike E Brand; Laila I Muderspach; Lynda D Roman; Annie A Yessaian; Huyen Q Pham; Koji Matsuo; Yvonne G Lin; Greg M McKee; Andres M Salazar; W Martin Kast
Journal:  Clin Immunol       Date:  2015-09-08       Impact factor: 3.969

Review 5.  Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.

Authors:  Joseph G Skeate; Andrew W Woodham; Mark H Einstein; Diane M Da Silva; W Martin Kast
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

6.  Immune Dysregulation in Patients Persistently Infected with Human Papillomaviruses 6 and 11.

Authors:  Alexandra V Lucs; James A DeVoti; Lynda Hatam; Ali Afzal; Allan L Abramson; Bettie M Steinberg; Vincent R Bonagura
Journal:  J Clin Med       Date:  2015-03       Impact factor: 4.241

Review 7.  The interplay between the vaginal microbiome and innate immunity in the focus of predictive, preventive, and personalized medical approach to combat HPV-induced cervical cancer.

Authors:  Erik Kudela; Alena Liskova; Marek Samec; Lenka Koklesova; Veronika Holubekova; Tomas Rokos; Erik Kozubik; Terezia Pribulova; Kevin Zhai; Dietrich Busselberg; Peter Kubatka; Kamil Biringer
Journal:  EPMA J       Date:  2021-05-18       Impact factor: 8.836

8.  Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C.

Authors:  Diane M Da Silva; Andrew W Woodham; Laurie K Rijkee; Joseph G Skeate; Julia R Taylor; Maaike E Koopman; Heike E Brand; Michael K Wong; Greg M McKee; Andres M Salazar; W Martin Kast
Journal:  Papillomavirus Res       Date:  2015-12-01

9.  Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.

Authors:  Diane M Da Silva; Andrew W Woodham; Paul H Naylor; James E Egan; Neil L Berinstein; W Martin Kast
Journal:  J Interferon Cytokine Res       Date:  2015-12-10       Impact factor: 2.607

10.  T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation.

Authors:  Andrew W Woodham; Lisa Yan; Joseph G Skeate; Daniel van der Veen; Heike H Brand; Michael K Wong; Diane M Da Silva; W Martin Kast
Journal:  Papillomavirus Res       Date:  2016-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.